Who Paid My Doc
Ravinder Shergill
Critical Care Medicine Vancouver, WA Medical Doctor
NPI 1053341099 CMS profile 507142
13305 Se Rivercrest Dr, Vancouver, WA 98683
General payments
$16,128
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ravinder Shergill of Vancouver, WA is reported in the CMS Open Payments database as having received $16,128 across 164 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $817 | 32 | |
| 2024 | General | $3,713 | 22 | |
| 2023 | General | $1,781 | 30 | |
| 2022 | General | $8,387 | 58 | |
| 2021 | General | $178 | 5 | |
| 2020 | General | $233 | 11 | |
| 2019 | General | $1,018 | 6 |
Beside peers
- Ravinder Shergill
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Ravinder Shergill were reported at $817. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Ravinder Shergill | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,018 | $149 | $51–$535 | $163 |
| 2020 | $233 | $110 | $30–$325 | $114 |
| 2021 | $178 | $125 | $34–$403 | $132 |
| 2022 | $8,387 | $157 | $49–$582 | $149 |
| 2023 | $1,781 | $162 | $56–$621 | $160 |
| 2024 | $3,713 | $168 | $53–$634 | $164 |
| 2025 | $817 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 33 drugsPart D claims
1,700
Drug cost
$811,047
Branded share of claims
36.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 139 | $218,494 | |
| Ambrisentan | Generic | 35 | $205,078 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 80 | $95,752 | |
| Fasenra Benralizumab | Brand | 13 | $75,975 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 55 | $55,178 | |
| Combivent Respimat Ipratropium/Albuterol Sulfate | Brand | 37 | $33,942 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 23 | $28,137 | |
| Bosentan | Generic | 12 | $14,934 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 30 | $14,766 | |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | Brand | 19 | $9,966 |
The 10 drugs with the highest cost, of 33 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 66 billing codesPaid by Medicare
$286,816
Medicare patients
444
Services billed
5,490
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| COPD | 66% | |
| Arthritis | 51% | |
| Heart failure | 41% | |
| Ischemic heart disease | 41% | |
| Diabetes | 31% | |
| Atrial fibrillation | 23% | |
| Depression | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 12 | 758 | $175 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 11 | 160 | $59 |
| Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg J7626 | Office | 13 | 31 | $28 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 | Office | 65 | 247 | $8 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
5 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| AIRSUPRA |
|
$139 | — | — |
| NUCALA |
|
$95 | — | — |
| Arikayce |
|
$82 | — | — |
| DUPIXENT |
|
$42 | — | — |
| FASENRA |
|
$21 | 13 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
164 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Washington
Vinay Gupta
Critical Care Medicine · Seattle, WA
Oliver McElvaney
Critical Care Medicine · Seattle, WA
Sharukh Lokhandwala
Critical Care Medicine · Seattle, WA
Kurt Jensen
Critical Care Medicine · Tacoma, WA
Chelsea Garner
Critical Care Medicine · Tacoma, WA
Nicholas Mark
Critical Care Medicine · Seattle, WA
Related records
Critical Care Medicine in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.